Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ross Stuart Berkowitz, M.D.

Co-Author

This page shows the publications co-authored by Ross Berkowitz and Neil Horowitz.
Connection Strength

12.075
  1. Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities. Gynecol Oncol. 2017 Jan; 144(1):208-214.
    View in: PubMed
    Score: 0.683
  2. Management of gestational trophoblastic neoplasia. Semin Oncol. 2009 Apr; 36(2):181-9.
    View in: PubMed
    Score: 0.404
  3. Consolidation chemotherapy in postmolar low-risk gestational trophoblastic neoplasia: a systematic review protocol. BMJ Open. 2022 Feb 24; 12(2):e059484.
    View in: PubMed
    Score: 0.247
  4. Clinical characteristics and thyroid function in complete hydatidiform mole complicated by hyperthyroidism. Gynecol Oncol. 2022 Apr; 165(1):137-142.
    View in: PubMed
    Score: 0.247
  5. Perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia: a systematic review of observational studies and meta-analysis. Am J Obstet Gynecol. 2021 Oct 09.
    View in: PubMed
    Score: 0.241
  6. A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease. Lancet Oncol. 2021 11; 22(11):1490-1491.
    View in: PubMed
    Score: 0.241
  7. Challenges in the Treatment of Low-risk Gestational Trophoblastic Neoplasia. Rev Bras Ginecol Obstet. 2021 Jul; 43(7):503-506.
    View in: PubMed
    Score: 0.239
  8. Impact of clinical characteristics on human chorionic gonadotropin regression after molar pregnancy. Clinics (Sao Paulo). 2021; 76:e2830.
    View in: PubMed
    Score: 0.239
  9. Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right? Gynecol Oncol. 2021 09; 162(3):638-644.
    View in: PubMed
    Score: 0.237
  10. Treatment of hydatidiform mole using manual vacuum aspiration: technical and tactical aspects. Int J Gynecol Cancer. 2021 09; 31(9):1299-1300.
    View in: PubMed
    Score: 0.235
  11. Video Hysteroscopy in the Diagnosis of Molar Pregnancy in two Challenging Situations: Complete Mole with Normal hCG and Partial Mole with Early Gestational Age. J Minim Invasive Gynecol. 2021 08; 28(8):1448-1449.
    View in: PubMed
    Score: 0.230
  12. Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance/relapsed disease. Best Pract Res Clin Obstet Gynaecol. 2021 Jul; 74:81-96.
    View in: PubMed
    Score: 0.230
  13. When less is more: regarding the use of chest X-ray instead of computed tomography in screening for pulmonary metastasis in postmolar gestational trophoblastic neoplasia. Br J Cancer. 2021 03; 124(6):1033-1034.
    View in: PubMed
    Score: 0.229
  14. Association between antioxidant vitamins and oxidative stress among patients with a complete hydatidiform mole. Clinics (Sao Paulo). 2020; 75:e1724.
    View in: PubMed
    Score: 0.221
  15. How to optimize the management of gestational trophoblastic disease during the coronavirus disease era? Am J Obstet Gynecol. 2020 10; 223(4):604-605.
    View in: PubMed
    Score: 0.219
  16. Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study. Gynecol Oncol. 2020 08; 158(2):452-459.
    View in: PubMed
    Score: 0.218
  17. Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America. Int J Gynecol Cancer. 2020 09; 30(9):1366-1371.
    View in: PubMed
    Score: 0.218
  18. Important insights for non-molar choriocarcinoma. BJOG. 2020 08; 127(9):1108.
    View in: PubMed
    Score: 0.217
  19. Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2020 05; 157(2):372-378.
    View in: PubMed
    Score: 0.214
  20. Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend. Gynecol Oncol. 2020 03; 156(3):598-605.
    View in: PubMed
    Score: 0.213
  21. Considering Changes in the Recommended Human Chorionic Gonadotropin Monitoring After Molar Evacuation. Obstet Gynecol. 2020 01; 135(1):9-11.
    View in: PubMed
    Score: 0.213
  22. State-of-the-Art Workup and Initial Management of Newly Diagnosed Molar Pregnancy and Postmolar Gestational Trophoblastic Neoplasia. J Natl Compr Canc Netw. 2019 11 01; 17(11):1396-1401.
    View in: PubMed
    Score: 0.211
  23. Continued hCG surveillance following chemotherapy for gestational trophoblastic neoplasia: When is enough enough? Gynecol Oncol. 2019 10; 155(1):1-2.
    View in: PubMed
    Score: 0.209
  24. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia? Gynecol Oncol. 2019 05; 153(2):277-285.
    View in: PubMed
    Score: 0.201
  25. Experience With the Use of an Online Community on Facebook for Brazilian Patients With Gestational Trophoblastic Disease: Netnography Study. J Med Internet Res. 2018 09 24; 20(9):e10897.
    View in: PubMed
    Score: 0.195
  26. In Reply. Obstet Gynecol. 2018 07; 132(1):218.
    View in: PubMed
    Score: 0.192
  27. Gestational Trophoblastic Disease Electronic Consults: What Do Patients and Physicians Want to Know? Int J Gynecol Cancer. 2018 05; 28(4):824-828.
    View in: PubMed
    Score: 0.190
  28. Manual Compared With Electric Vacuum Aspiration for Treatment of Molar Pregnancy. Obstet Gynecol. 2018 04; 131(4):652-659.
    View in: PubMed
    Score: 0.189
  29. Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma? Gynecol Oncol. 2018 02; 148(2):239-246.
    View in: PubMed
    Score: 0.185
  30. Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute. Gynecol Oncol. 2018 01; 148(1):5-11.
    View in: PubMed
    Score: 0.184
  31. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Gynecol Oncol. 2018 01; 148(1):161-167.
    View in: PubMed
    Score: 0.183
  32. Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review. Gynecol Oncol. 2017 Apr; 145(1):88-95.
    View in: PubMed
    Score: 0.174
  33. Effect of race/ethnicity on risk of complete and partial molar pregnancy after adjustment for age. Gynecol Oncol. 2016 10; 143(1):73-76.
    View in: PubMed
    Score: 0.168
  34. Gestational Trophoblastic Disease: Presentations from the XVIIIth World Congress on Gestational Trophoblastic Diseases. J Reprod Med. 2016 May-Jun; 61(5-6):185-6.
    View in: PubMed
    Score: 0.165
  35. Maternal Near Miss According to World Health Organization Classification Among Women with a Hydatidiform Mole: Experience at the New England Trophoblastic Disease Center, 1994-2013. J Reprod Med. 2016 May-Jun; 61(5-6):210-4.
    View in: PubMed
    Score: 0.165
  36. Effect of race/ethnicity on clinical presentation and risk of gestational trophoblastic neoplasia in patients with complete and partial molar pregnancy at a tertiary care referral center. Am J Obstet Gynecol. 2016 09; 215(3):334.e1-6.
    View in: PubMed
    Score: 0.165
  37. Clinical Presentation of Complete Hydatidiform Mole and Partial Hydatidiform Mole at a Regional Trophoblastic Disease Center in the United States Over the Past 2 Decades. Int J Gynecol Cancer. 2016 Feb; 26(2):367-70.
    View in: PubMed
    Score: 0.162
  38. The effect of adolescence and advanced maternal age on the incidence of complete and partial molar pregnancy. Gynecol Oncol. 2016 Mar; 140(3):470-3.
    View in: PubMed
    Score: 0.162
  39. Optimal management of low-risk gestational trophoblastic neoplasia. Expert Rev Anticancer Ther. 2015; 15(11):1293-304.
    View in: PubMed
    Score: 0.159
  40. Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia? Gynecol Oncol. 2015 Jul; 138(1):46-9.
    View in: PubMed
    Score: 0.154
  41. Response to chemotherapy in overweight/obese patients with low-risk gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2015 May; 25(4):734-40.
    View in: PubMed
    Score: 0.154
  42. Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2015 Jul; 138(1):50-4.
    View in: PubMed
    Score: 0.154
  43. Gestational trophoblastic disease: presentations from the XVIIth World Congress on Gestational Trophoblastic Diseases. J Reprod Med. 2014 May-Jun; 59(5-6):187.
    View in: PubMed
    Score: 0.144
  44. What is the optimal treatment for obese patients with advanced ovarian carcinoma? Am J Obstet Gynecol. 2014 Sep; 211(3):231.e1-9.
    View in: PubMed
    Score: 0.143
  45. Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol. 2013 Aug; 130(2):312-6.
    View in: PubMed
    Score: 0.135
  46. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol. 2013 Apr; 129(1):69-73.
    View in: PubMed
    Score: 0.132
  47. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013 Apr; 129(1):63-8.
    View in: PubMed
    Score: 0.132
  48. A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia. J Reprod Med. 2012 May-Jun; 57(5-6):211-8.
    View in: PubMed
    Score: 0.125
  49. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012 May; 125(2):362-6.
    View in: PubMed
    Score: 0.123
  50. The epidemiology of ovarian granulosa cell tumors: a case-control study. Gynecol Oncol. 2009 Nov; 115(2):221-5.
    View in: PubMed
    Score: 0.104
  51. Vascularization and expression of angiogenic factors in partial and complete molar pregnancies. J Reprod Med. 2008 Aug; 53(8):589-94.
    View in: PubMed
    Score: 0.097
  52. ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma. Oncogene. 2022 Mar 18.
    View in: PubMed
    Score: 0.062
  53. Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer. Int J Gynecol Cancer. 2021 10; 31(10):1341-1347.
    View in: PubMed
    Score: 0.060
  54. Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers (Basel). 2021 Jun 28; 13(13).
    View in: PubMed
    Score: 0.059
  55. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Lancet Oncol. 2021 08; 22(8):1188-1198.
    View in: PubMed
    Score: 0.059
  56. Loss of Selenoprotein Iodothyronine Deiodinase 3 Expression Correlates with Progression of Complete Hydatidiform Mole to Gestational Trophoblastic Neoplasia. Reprod Sci. 2021 11; 28(11):3200-3211.
    View in: PubMed
    Score: 0.059
  57. Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions. Cancers (Basel). 2021 May 03; 13(9).
    View in: PubMed
    Score: 0.058
  58. Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer. Ann Surg Oncol. 2021 Oct; 28(11):6705-6713.
    View in: PubMed
    Score: 0.058
  59. Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples. Am J Reprod Immunol. 2021 07; 86(1):e13394.
    View in: PubMed
    Score: 0.058
  60. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res. 2021 01 01; 81(1):158-173.
    View in: PubMed
    Score: 0.056
  61. Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression. Am J Obstet Gynecol. 2021 04; 224(4):372.e1-372.e30.
    View in: PubMed
    Score: 0.056
  62. Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy. Gynecol Oncol. 2020 12; 159(3):751-757.
    View in: PubMed
    Score: 0.056
  63. Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study. Curr Probl Cancer. 2021 02; 45(1):100622.
    View in: PubMed
    Score: 0.055
  64. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer. Int J Gynecol Cancer. 2020 07; 30(7):1052-1057.
    View in: PubMed
    Score: 0.055
  65. EMA vs EMACO in the treatment of gestational trophoblastic neoplasia. Gynecol Oncol. 2020 07; 158(1):99-104.
    View in: PubMed
    Score: 0.055
  66. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. Am J Obstet Gynecol. 2019 10; 221(4):326.e1-326.e7.
    View in: PubMed
    Score: 0.051
  67. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol. 2019 May; 38(3):230-240.
    View in: PubMed
    Score: 0.051
  68. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma. Int J Gynecol Cancer. 2019 03; 29(3):585-592.
    View in: PubMed
    Score: 0.050
  69. Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter? Gynecol Oncol. 2019 04; 153(1):63-67.
    View in: PubMed
    Score: 0.050
  70. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. J Pathol. 2018 11; 246(3):344-351.
    View in: PubMed
    Score: 0.049
  71. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 11; 8(11):1404-1421.
    View in: PubMed
    Score: 0.049
  72. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery? Gynecol Oncol. 2018 08; 150(2):233-238.
    View in: PubMed
    Score: 0.048
  73. The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts. Gynecol Oncol. 2018 07; 150(1):67-72.
    View in: PubMed
    Score: 0.047
  74. Extramammary Paget Disease of the Vulva: A Case Series Examining Treatment, Recurrence, and Malignant Transformation. Int J Gynecol Cancer. 2018 03; 28(3):632-638.
    View in: PubMed
    Score: 0.047
  75. Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome. Int J Gynecol Pathol. 2017 Mar; 36(2):115-127.
    View in: PubMed
    Score: 0.044
  76. Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA. Mod Pathol. 2017 03; 30(3):448-458.
    View in: PubMed
    Score: 0.043
  77. Investigating the Impact of Body Mass Index on Intraperitoneal Chemotherapy Outcomes in Ovarian and Fallopian Tube Cancer. Int J Gynecol Cancer. 2016 07; 26(6):1033-40.
    View in: PubMed
    Score: 0.042
  78. Timing of Referral to the New England Trophoblastic Disease Center: Does Referral with Molar Pregnancy Versus Postmolar Gestational Trophoblastic Neoplasia Affect Outcomes? J Reprod Med. 2016 May-Jun; 61(5-6):187-91.
    View in: PubMed
    Score: 0.041
  79. Erratum to: Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1611.
    View in: PubMed
    Score: 0.040
  80. Erratum to: Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1606-7.
    View in: PubMed
    Score: 0.040
  81. Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial Cancer. Ann Surg Oncol. 2016 Jan; 23(1):178-85.
    View in: PubMed
    Score: 0.039
  82. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015 Feb 26; 160(5):977-989.
    View in: PubMed
    Score: 0.038
  83. Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell carcinoma of the vulva? Gynecol Oncol. 2015 Apr; 137(1):60-5.
    View in: PubMed
    Score: 0.038
  84. Anesthetic selection and disease-free survival following optimal primary cytoreductive surgery for stage III epithelial ovarian cancer. Ann Surg Oncol. 2015 Apr; 22(4):1341-8.
    View in: PubMed
    Score: 0.037
  85. Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol. 2014 Oct; 135(1):54-7.
    View in: PubMed
    Score: 0.037
  86. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol. 2014 Feb; 132(2):280-6.
    View in: PubMed
    Score: 0.035
  87. A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. Gynecol Oncol. 2014 Jan; 132(1):55-60.
    View in: PubMed
    Score: 0.035
  88. Prognostic determinants in patients with uterine and ovarian clear carcinoma. Gynecol Oncol. 2012 May; 125(2):376-80.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.